Provided by Tiger Trade Technology Pte. Ltd.

REVOLUTION MEDICINES INC C/WTS (TO PUR COM)

1.80
-0.0500-2.70%
Volume:9.51K
Turnover:17.11K
Market Cap:336.48M
PE:-0.35
High:1.85
Open:1.83
Low:1.68
Close:1.85
52wk High:3.59
52wk Low:0.0305
Shares:186.93M
Float Shares:186.93M
Volume Ratio:1.11
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1779
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Company Profile

Company Name:
REVOLUTION MEDICINES INC C/WTS (TO PUR COM)
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.